ERBB2 and lung cancer: In addition, T‐DM1 was also investigated in other HER2‐positive solid tumors, including gastric cancer (GATSBY trial, T‐DM1 vs. taxane, without superior benefit) 129, 130 and lung cancer (NCT02675829 trial, PR rate: 44%, median PFS: 5 months; NCT02289833 trial, ORR: 20%; CBR: 30%).131, 132